Insulet (NASDAQ:PODD) Trading 4.4% Higher After Insider Buying Activity

Insulet Corporation (NASDAQ:PODD) shot up 4.4% during mid-day trading on Friday following insider buying activity. The stock traded as high as $154.49 and last traded at $152.8990. 343,377 shares were traded during mid-day trading, a decline of 71% from the average session volume of 1,171,243 shares. The stock had previously closed at $146.41.

Specifically, Director Timothy C. Stonesifer bought 2,790 shares of Insulet stock in a transaction that occurred on Wednesday, June 3rd. The shares were purchased at an average price of $143.51 per share, with a total value of $400,392.90. Following the completion of the acquisition, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Rothschild & Co Redburn reaffirmed a “neutral” rating and set a $220.00 price target (down from $380.00) on shares of Insulet in a report on Friday, April 24th. Wall Street Zen upgraded Insulet from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Stifel Nicolaus decreased their target price on Insulet from $350.00 to $250.00 in a research note on Thursday, May 7th. Oppenheimer lowered their price target on Insulet from $300.00 to $210.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Finally, Barclays dropped their price target on shares of Insulet from $286.00 to $198.00 and set an “underweight” rating on the stock in a research note on Thursday, May 7th. Twenty-one investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $252.04.

Insulet Stock Performance

The company has a market cap of $10.60 billion, a PE ratio of 35.48, a PEG ratio of 1.13 and a beta of 1.13. The stock has a 50 day simple moving average of $176.99 and a two-hundred day simple moving average of $239.50. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.23. The company had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. Insulet’s revenue for the quarter was up 33.9% on a year-over-year basis. During the same period last year, the firm posted $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities analysts predict that Insulet Corporation will post 6.44 EPS for the current year.

Hedge Funds Weigh In On Insulet

A number of large investors have recently modified their holdings of PODD. Nordea Investment Management AB boosted its holdings in Insulet by 35.0% during the fourth quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier’s stock worth $157,128,000 after buying an additional 142,922 shares in the last quarter. ING Groep NV lifted its holdings in shares of Insulet by 88.5% in the third quarter. ING Groep NV now owns 17,300 shares of the medical instruments supplier’s stock valued at $5,341,000 after purchasing an additional 8,123 shares in the last quarter. Jain Global LLC lifted its stake in Insulet by 148.2% in the 3rd quarter. Jain Global LLC now owns 106,710 shares of the medical instruments supplier’s stock valued at $32,945,000 after buying an additional 63,719 shares in the last quarter. Fisher Asset Management LLC boosted its stake in shares of Insulet by 38.1% during the third quarter. Fisher Asset Management LLC now owns 46,273 shares of the medical instruments supplier’s stock valued at $14,286,000 after acquiring an additional 12,754 shares during the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp lifted its holdings in Insulet by 26.5% in the 4th quarter. Mitsubishi UFJ Trust & Banking Corp now owns 43,921 shares of the medical instruments supplier’s stock valued at $12,484,000 after purchasing an additional 9,206 shares in the last quarter.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.